Two months after COVID-19 vaccines were rolled out to the public, a statistically significant safety signal for myocarditis in males ages 8 to 21 appeared in the Centers for Disease Control’s Vaccine Adverse Event Reporting System — but CDC officials waited another three months before alerting the public, according to a new study.
Two months after COVID-19 vaccines were rolled out to the U.S. public, a statistically significant vaccine safety signal for myocarditis in males ages 8 to 21 appeared in the Centers for Disease Control’s (CDC) Vaccine Adverse Event Reporting System (VAERS) — but CDC officials waited another three months before alerting the public, according to a new study.
The study, “Delayed Vigilance: A Comment on Myocarditis in Association with the COVID-19 Injections,” by Karl Jablonowski, Ph.D., and Brian Hooker, Ph.D., P.E., was published on Oct. 17 in the International Journal of Vaccine Theory, Practice, and Research.
In an interview with The Defender, Hooker, chief scientific officer for Children’s Health Defense, said...
“This important paper shows that a strong, statistically significant vaccine adverse event ‘signal’ for myocarditis in males 8 to 21 years of age was seen on the VAERS database as early as Feb. 19, 2021, just two months after the release of the COVID-19 vaccine to the U.S. public.
“Instead of sounding the alarm regarding this signal, CDC officials buried the connection between COVID-19 vaccination and myocarditis until May 27, 2021. By this date, over 50% of the eligible U.S. population had received at least one mRNA COVID-19 vaccine.
“Withholding this type of information is criminal...”
To read more visit CDMedia.
